This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biederman, J.
Right arrow Articles by Schuh, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biederman, J.
Right arrow Articles by Schuh, K. J.
Related Collections
Right arrow Therapeutics & Toxicology

PEDIATRICS Vol. 110 No. 6 December 2002, pp. e75

ELECTRONIC ARTICLE

Efficacy of Atomoxetine Versus Placebo in School-Age Girls With Attention-Deficit/Hyperactivity Disorder

Joseph Biederman, MD*, John H. Heiligenstein, MD{ddagger}, Douglas E. Faries, PhD{ddagger}, Nora Galil, MD§, Ralf Dittmann, MD, PhD||, Graham J. Emslie, MD, Christopher J. Kratochvil, MD#, Harry F. Laws, MD{ddagger} and Kory J. Schuh, PhD{ddagger} Atomoxetine ADHD Study Group

* Massachusetts General Hospital, Boston, Massachusetts
{ddagger} Lilly Research Laboratories, Indianapolis, Indiana
§ Neuroscience Inc, Bethesda, Maryland
|| Lilly Deutschland GmbH, Bad Homburg, and Psychosomatic Department, Children’s Hospital, University of Hamburg, Hamburg, Germany
University of Texas Southwestern Medical Center, Dallas, Texas
# University of Nebraska Medical Center, Omaha, Nebraska

--> Objective. The efficacy of atomoxetine was assessed in school-age girls with attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporter with minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors.

Methods. A total of 291 children who were 7 to 13 years of age and met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for ADHD participated in 1 of 2 combined, double-blind, placebo-controlled, multisite, identical clinical trials. This intent-to-treat subset analysis examined the effects of atomoxetine versus placebo in 51 girls who were randomized to atomoxetine (n = 30) or placebo (n = 21) for 9 weeks. ADHD symptoms were assessed using parent- and investigator-rated scales.

Results. Atomoxetine was superior to placebo on the following measures: the Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score; the Inattentive and Hyperactive/Impulsive subscales of the Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score; the ADHD Index subscale of the Conners’ Parent Rating Scale-Revised: Short Form; and the Clinical Global Impressions of Severity of ADHD. Statistically significant efficacy was seen 1 week after randomization and remained so for the duration of the study. One patient from each of the atomoxetine and placebo groups discontinued the study as a result of an adverse event.

Conclusion. Atomoxetine was found to be effective and well tolerated for the treatment of ADHD in school-age girls.

Key Words: atomoxetine • ADHD • school-age • girls • nonstimulant

Abbreviations: ADHD, attention-deficit/hyperactivity disorder • DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition • ADHD RS, Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score • SD, standard deviation • CPRS-R, Conners’ • Parent Rating Scale-Revised: Short Form • CGI-ADHD-S, Clinical Global Impressions of Severity of ADHD

Received for publication Apr 30, 2002; Accepted Aug 14, 2002.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-H. Kim, M. K. Hahn, Y. Joung, S. L. Anderson, A. H. Steele, M. S. Mazei-Robinson, I. Gizer, M. H. Teicher, B. M. Cohen, D. Robertson, et al.
A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder
PNAS, December 12, 2006; 103(50): 19164 - 19169.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. J. Allen, R. M. Kurlan, D. L. Gilbert, B. J. Coffey, S. L. Linder, D. W. Lewis, P. K. Winner, D. W. Dunn, L. S. Dure, F. R. Sallee, et al.
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
Neurology, December 27, 2005; 65(12): 1941 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
J Barton
Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder
Arch. Dis. Child., February 1, 2005; 90(suppl_1): i26 - i29.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. NewsHome page
J. Rosack

Psychiatr News, January 3, 2003; 38(1): 18 - 18.
[Full Text]